Jazz strikes another chord in neuroscience via $7.2B GW pickup

With the acquisition of cannabinoid therapeutics company GW in Jazz’s largest deal ever, the company added a product and pipeline that complements its historical strength in neuroscience rather than oncology, where it has sought to grow in recent years.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will pay $220 per share to acquire GW Pharmaceuticals plc (NASDAQ:GWPH), with the majority in cash alongside a $20-per-share stock component. The deal values GW at $7.2 billion, or $6.7 billion net of cash, and comes at a premium of just over 50% above GW’s closing price Tuesday of $146.25...